



Leave Nothing Behind with Atherectomy with

Jetstream


Chul-Min Ahn

Professor, Division of Cardiology Director of Cardiac Critical Care Unit Severance Cardiovascular Hospital Yonsei University College of Medicine Seoul, South Korea





Unique anatomy & Biomechanics



- High prevalence of diffuse/calcified/thrombotic disease
- Different mechanical forces \rightarrow deformed in multiple directions by leg movement



Artherectomy and Anti-restenotic Tx


Limitations of DCB : Lesion Length

Scaffolds still needed, likely at rates proportional to lesion complexity




Provisional stent rates in DCB trials trend with lesion length

RAART



Atherectomy



Atherectomy enlarges the vascular lumen by <u>removing tissue</u> with little vessel stretching where as balloon angioplasty and stenting have their predominant effect as a direct result of <u>vessel stretching</u>

YON SEI UNIVERSITY

Stent


Calcium Reduces DCB Efficacy

- 60 pts with SFA stenosis or occlusion treated with DCB
- CTA, DSA, and IVUS used to quantify the calcium burden
- At 1 year, greater calcification was associated with:
 - patency- 50% for 270°-360° vs 100% for 0°-90°
 - ankle-brachial index




- late lumen loss and TLR
- DEFINITIVE AR: directional atherectomy + DCB vs DCB alone

	DCB	Atherectomy + DCB	Atherectomy + DCB (Severe Ca ²⁺)
Technical Success	64.2%	89.6%	84.2%
Bailout stent	3.7%	0%	5.3%
Flow- limiting Dissection	19%	2%	0%



Fanelli F, et al. Cardiovasc Intervent Radiol. 2014;37(4):898--907.




YONSE UNIVERSIT

Calcium Makes More Complications

- Calcium is heavily present in peripheral lesions¹
- Presence of calcium necessitates greater balloon pressures^{2,3}
- Plaques associated with arterial dissections commonly have significant calcium deposits⁵


Calcium Increases Arterial Resistance to Balloon Dilation²



Bishop, et al. Ann Vasc Surg. 2008;22:799--805.
 Demer. Circulation. 1991;83:2083--2093.
 Makam. J Invasive Cardiol. 2013;25(2):85--8.

Calcium Limits Vessel Expansion


Significant difference in vessel compliance leads to overstretch in non-diseased tissue causing dissections, recoil, excessive injury, and poor outcomes





Severance Cardiovascular Hospital, Yonsei University Health Syst 5. Fitzgerald, et al. Cardiovasc Intervent Radiol. 2014 ;37(4):898-907.

Current Available Arterectomy Devices






Rotational Device Characteristics

- Front-cutting
 - Immediately engage the lesion
 - Facilitate guidewire placement across a CTO
- Differential cutting



Jetstream (Boston Scientific)

- Cut one material while sparing another based on differences in composition
- Elastic tissue (vessel wall) deflects away from the atherectomy device while inelastic tissue
 - (plaque) is selectively ablated




ACTIVE ASPIRATION: The only atherectomy device with Active Aspiration

CONCENTRIC LUMENS: Rotational, expandable blades maximize luminal gain through debulking




JETSTREAM Catheter : XC and SC

JETSTREAM XC Catheters



JETSTREAM SC Catheters



Confirm the Minimum Vessel Diameter **Proximal to the Lesion**

Jetstream _{XC}	\odot	Minimum Vessel Diameter Blades Down	3.5 mm
Atherectomy Catheter O 2.4 MM 5 3.4 MM	Minimum Vessel Diameter Blades Up	4.5 mm	
Jetstream _{xc}	\odot	Minimum Vessel Diameter Blades Down	3.0 mm
Atherectomy Catheler O 2.1 MM 5 3.0 MM		Minimum Vessel Diameter Blades Up	4.0 mm
			1
JETSTREAM SC Atherectomy Catheter	T	Minimum Vessel Diameter Blades Down	2.75 mm

Minimum Vessel Diameter Blades Down 2.5 mm



Severance Cardiovascular Hospital, Yonsei University Health System

O 1.85 MM

Q 1.6 MM

ETSTREAMSC

JETSTREAM Advantages **HAWK-series JETSTREAM** VS 3.5 min 50 minutes **Running Time** Luminal Shape 0 Х In-Stent Restenosis, In-Stent Occlusion, Calcium Indication Х 0 **BTK Indication Cutting Tip Design**



Jetstream Clinical Studies

Pathway PVD study

172 patients at 9 European centers

51% had lesions with moderate to high calcium, 31% total occlusions

74% TLR-free at 12 months

Patients with diabetes had MAE rates and clinical improvement similar to those without diabetes

Jetstream Calcium Study

26 pts with moderately to severely calcified femoropopliteal artery lesions

Lumen area increased significantly after treatment with Jetstream; calcium reduction was responsible for 86% of the lumen increase

JET Registry Post-market registry of 241 patients at 37 US centers


Mean lesion length 16 cm, 48% calcium grade 3 or 4, 36% total occlusions

22.8% 12-month restenosis rate 81.7% TLR/TVR-free rate at 12 months Zeller et al. J Endovasc Ther 2009;16:653–662. Sixt et al. Ann Vasc Surg 2011; 25:520-529. Maehara A, et al. EuroIntervention 2015; 19;11:96-103. Garcia LA, et al. LINC 2017



JET-SCE -Jetstream + DCB vs Jetstream + PTA

- Retrospective study of patients receiving Jetstream atherectomy to treat femoropopliteal obstructive disease
- N=75
- Treated Apr 2012 -Dec 2014 adjunctive PTA (N=50)
- Treated Dec 2014–Jul 2016 -adjunctive DCB (N=25)
- Median treated length (p=0.053)
 - Adjunctive PTA: 15 cm
 - DCB: 10 ст






Long-Term Outcomes After Percutaneous Lower Extremity Arterial Interventions With Atherectomy vs. Balloon Angioplasty

- Propensity Score-Matched Registry -



Circ J 2017; **81:** 376–382 doi:10.1253/circj.CJ-16-0856

Adam Janas, MD, PhD; Piotr P. Buszman, MD, PhD; Krzysztof P. Milewski, MD, PhD; Szymon Wiernek, MD, PhD; Ksenia Janas, MD; Maciej Pruski, MD; Wojciech Wojakowski, MD, PhD; Aleksandra Błachut, MD; Wojciech Picheta, MD; Pawel Buszman, MD, PhD; Stefan Kiesz, MD






Outcomes of Adjunctive Drug-Coated Versus Uncoated Balloon after Atherectomy in Femoropopliteal Artery Disease

Yun-Jeong Lee,¹ Young-Guk Ko,² Chul-Min Ahn,² Sung-Jin Hong,² Jung-Sun Kim,² Byeong-Keuk Kim,² Donghoon Choi,² Myeong-Ki Hong,² and Yangsoo Jang,² Jeju-si and Seoul, Republic of Korea Ann Vasc Surg 2020; 68: 391–399

- 115 pts, 126 femoropopliteal disease, atherectomy
- Group A : 66 DCB vs. Group B: 60 POBA
- July 2009 to March 2018





Variables	Univariate analysis		Multivariate analysis	
	HR (CI)	<i>P</i> -value	HR (CI)	P-value
Hypertension	0.51 (0.25-1.04)	0.064	0.48 (0.23-1.01)	0.053
ESRD	1.87 (1.01-3.45)	0.044	1.88 (0.93-3.78)	0.078
Critical limb ischemia	2.02 (1.20-3.42)	0.009	1.47 (0.81-2.65)	0.204
TASC II type D lesion	2.58 (1.52-4.40)	< 0.001	1.86 (0.94-3.68)	0.074
Total occlusion	1.67 (0.99-2.82)	0.053	1.06 (0.55-2.04)	0.865
ISR lesion	2.25 (1.32-3.83)	0.003	1.95 (1.11-3.42)	0.020
DCB use	0.57 (0.33-0.98)	0.041	0.53 (0.30-0.93)	0.026
Directional atherectomy	0.78 (0.39-1.55)	0.471		
First 30 atherectomy cases	1.06 (0.58-1.91)	0.859		

Table III. Cox proportional hazard regression analysis for factors associated with loss of clinical patency after atherectomy

Table IV. Cox proportional hazard regression analysis for factors associated with loss of clinical patency after atherectomy plus drug-coated balloon

	Univariate analysis		Multivariate analysis		
Variables	HR (CI)	<i>P</i> -value	HR (CI)	P-value	
Age	0.94 (0.91-0.98)	0.001	0.94 (0.90-0.99)	0.016	
Male	0.37 (0.15-0.92)	0.032	0.65 (0.21-2.06)	0.464	
Hypertension	0.36 (0.12-1.07)	0.067	0.61 (0.15 - 2.43)	0.480	
ESRD	2.33 (0.94-5.74)	0.067	1.32(0.44 - 4.02)	0.622	
TASC II D	4.43 (1.88-10.44)	0.001	1.60(0.55 - 4.66)	0.388	
Total occlusion	2.26 (0.97-5.27)	0.060	1.30 (0.46-3.65)	0.619	
ISR lesion	3.77 (1.54-9.19)	0.004	2.90 (0.97-8.68)	0.057	
Provisional stenting	11.91 (3.06-46.31)	< 0.001	9.78 (2.20-43.46)	0.003	
Directional atherectomy	0.71 (0.29-1.71)	0.439			

Ann Vasc Surg 2020; 68: 391-399

UNIVERSITY


Clinical Investigation

Clinical Safety and Efficacy of Rotational Atherectomy in Japanese Patients with Peripheral Arterial Disease Presenting Femoropopliteal Lesions: The J-SUPREME and J-SUPREME II Trials

Purpose: The purpose of the J-SUPREME (J-S) and J-SUPREME II (J-SII) trials was to evaluate the performance of the Jetstream Atherectomy System for the treatment of Japanese patients with symptomatic occlusive atherosclerotic lesions in the superficial femoral and popliteal arteries. Materials and Methods: The |-S and |-SII trials were both prospective, multicenter, single-arm clinical trials. Patients in J-S underwent Jetstream atherectomy followed by percutaneous transluminal angioplasty (PTA), whereas those in J-SII had adjunctive drug-coated balloon (DCB) treatment following atherectomy. Patients were adults with Rutherford category 2, 3, or 4 and had stenotic, restenotic, or occlusive lesion(s) with a degree of stenosis \geq 70 in the superficial femoral artery and/or proximal popliteal artery. In |-S, lesions were required to be calcified, and in J-SII lesions were required to be severely calcified. Results: A total of 50 patients were enrolled in J-S (mean age 72.3±8.7 years, lesion length 82.0±41.5 mm, 36% calcification PACSS Grade 3, 22% Grade 4) and 31 patients in J-SII (mean age 72.5±7.7 years, lesion length 122.6±55.6 mm, 19.4% calcification PACSS Grade 3, 77.4% Grade 4). No bailout stenting or bypass conversions were required. No major adverse events (MAEs) were reported for either trial through I month. The 6-month primary patency for J-S, with PTA alone following atherectomy, was 40.4% (19/47). The 6-month primary patency for J-SII, with DCB treatment following atherectomy, was 96.7% (29/30). At 6-month post-procedure, 79.2% (38/48) of patients in J-S, and 100% (30/30) of patients in J-SII had improved by at least I Rutherford category. Conclusion: J-SUPREME trial results demonstrate procedural safety and efficacy of the Jetstream Atherectomy System and J-SII showed sustained patency through 6 months following combination treatment with letstream atherectomy and DCB.

- Osamu Iida, MD¹⁽¹⁾, Kazushi Urasawa, MD², Yoshisato Shibata, MD³, Yoshito Yamamoto, MD⁴, Hiroshi Ando, MD⁵, Masahiko Fujihara, MD⁶⁽¹⁾, Tatsuya Nakama, MD⁷⁽¹⁾, Yusuke Miyashita, MD⁸, Shinsuke Mori, MD⁹⁽¹⁾, Juan Diaz-Cartelle, MD¹⁰, and Yoshimitsu Soga, MD¹¹⁽¹⁾

Journal of Endovascular Therapy 2021





	J-SUPREME (N=50)	J-SUPREME II (N=31)
Lesion success rate ^a	NA	80.6% (25/31)
Procedural success rate ^b	100% (50/50)	100% (31/31)
Reduction in lesion stenosis ^c	36. I ± I 4.4%	34.6±16.0%
Primary patency at 6 months	40.4% (19/47) ^d	96.7% (29/30) ^e
Primary sustained clinical improvement ^f	79.2% (38/48)	100% (30/30)
Hemodynamic improvement ^g	68.1% (32/47)	73.3% (22/30)
MAE ^h : I month	0%	0%
All causes of deaths	0%	0%
Target limb major amputation	0%	0%
Target lesion revascularization	0%	0%
MAE: 6 months	10.0% (5/50)	0%
Target limb major amputation	0%	0%
Target lesion revascularization	10.0% (5/50)	0%
MAE: 12 months	26.0% (13/50)	NA
Target limb major amputation	0%	NA
Target lesion revascularization	26.0% (13/50)	NA
All deaths through follow-up	2.0% (1/50)	0%

Table 3. Per-Protocol Endpoints, Clinical Outcomes, and MAEs.



JET-RANGER Clinical Study

Enrolling

Clinical Study Over	rview: JET-RANGER (Investigator sponsored IDE)*			
Title	<u>JET</u> Stream Athe <u>R</u> ectomy With <u>A</u> djunctive Paclitaxel-Coated Balloo <u>N</u> Angioplasty vs Plain Old Balloon An <u>G</u> ioplasty Followed by Paclitaxel-Coated Balloon in Treating Compl <u>E</u> x Denovo Femo <u>R</u> opopliteal Arterial Disease (JET-RANGER)			
Principal Investigator/ Sponsor	Nicolas W. Shammas, MD Midwest Cardiovascular Research Foundation			
Objective	Test the hypothesis that Jetstream atherectomy followed by DCB (Ranger or IN.F Paclitaxel Drug Coated Balloon) improves target lesion revascularization at 1 year when compared to balloon angioplasty followed by DCB in the treatment of femoropopliteal arterial de novo disease			
Study Design	Prospective, multicenter, randomized study Jetstream + DCB vs PTA + DCB (2:1 randomization)		Recruitment Status () :	Enrolling by invitation
Patients	255 patients at up to 25 US sites Rutherford category 2-4 and ≥70% de novo stenosis with: lesion length ≥10 cm, or chronic total occlusion (any length) in the SFA and/or popliteal artery, or calcification of ≥ grade by PACCS		ary Completion Date 1 : udy Completion Date 1 :	
Endpoints	Effectiveness: Target Lesion Revascularization at 1 Year: intra-procedural bail out the index lesion is considered meeting a TLR endpoint. Safety: Major Adverse Events (MAE) at 30 days: unplanned amputation, total mo TLR at 30 days (TLR includes bail out stenting)	Ū	ov Identifier: NCT032067 n the FDA	762
	Severance Cardiovascular Hospital, Yonsei University Heal	lth Sy <u>stem</u>		

Tips of Rotational atherectomy

- 1. Slow advancement 1mm/1sec, Don't strong push !!
 - ✓ High pitch sound or rotational failure → static/slower procedure
- 2. Intermittent cool down 30sec/flushing (Rex mod)
 - ✓ Prevent Wire & device stucking / Advancement failure
- 3. Distal protection device usually recommended, especially in CLI pts
 - ✓ Small balloon for resistance to advancement of filter device
- 4. Steep aortic bifurcation angle fluoroscopic guided device transfer
- 5. Don't perforem intra-sheath device can stuck in side of sheath or sheath fracture




Benefit & Limitation of Rotational atherectomy

- Benefit
 - Long & tight lesion
 - Circumferential calcium
 - Active aspiration
 - Concentric Lumen

- Limitation
 - Distal embolization
 - Wire & Device stucking
 - Learning curve
 - Passage failure BTK lesion




Case Rotational atherectomy F/67



Case – M/84 yo


- Chief complaint
 - Claudication(both, Rutherfold 3, 1YA)
- *PHx*
 - Poor controlled DM (HbA1C 9.5%)
 BPH
 - Ex-smoker(0.5pack/d X 24yrs, 40YA D/C)
- Lab
 - BUN/Cr: 26.7 mg/dL / 1.29 mg/dL(eGFR 53 ml/min/1.73m²)
 - T.Chol/TG/HDL/LDL : 192/175/50/107 mg/dL




ABI(Ankle / Brachial Index) → Rt: 0.70 / Lt: 0.61



CT Lower Extremity Angio




Lt SFA – ultrasound guided wiring





Intraluminal wiring & IVUS






Jetstream Atherectomy & post-IVUS






POBA- NC balloon (5x200) – post IVUS





DCB(5x150)







Stent Insertion (InnovaTM, 6x80) for flow limiting dissection & IVUS











VIDER

My Recent Strategy for Device Selection for femoropopliteal lesion

✓ Clear Vessel with Visible thrombi/Recent Onset/graft vessel - No wire resistance
 → AngioJet with thrombolysis + POBA or BMS

✓ Mixed lesion with mild calcification

- → Wiring Resistance
 - \rightarrow High \rightarrow Jetstream + DCB
 - \rightarrow Low \rightarrow Rotarex + POBA/DCB

✓ Long CTO with calcification

→Mild calcification/No big resistance → Consider Rotarex first

→Moderate to severe calcification → Sono/Angio-guided truelumen wiring

 \rightarrow Jetstream + DCB \rightarrow Bailout BMS

 \rightarrow Mixed wiring \rightarrow IVUS or Balloon response

- \rightarrow > 85 % true lumen wiring \rightarrow atherectomy device \rightarrow DCB
- \rightarrow < 85 % NC balloon \rightarrow DCB or DES
- \rightarrow Good response to balloon response \rightarrow DCB
- → Dissection + → Consider focal DES/BMS

Take Home Message

1. Complex F-P lesions (Long, calcified, CTO lesions etc) lesions still remain challenging for simple angioplasty and DCB.

2. Lesion Characteristic (Calcium/long lesions) should be considered for selection of proper Atherectomy *→* Increased Lumen Gain, less bail-out stenting & more patency.

3. Efficacy of RAART is a logical treatment strategy for use in long, complex, and calcified lesions for effective immediate procedural success and maintenance of patency.

Thank you for kind attention !! With the Love of God, Free Humankind from Disease and Suffering

Severance



